Novartis set to threaten Mylan's EpiPen franchise

The Swiss pharma will provide commercial might for a competing epinephrine autoinjector. 

By Lisa LaMotta • July 2, 2018

Novartis to spin out Alcon into standalone device company

After months of weighing its options, the Swiss pharma is focusing in on therapeutics and shedding its ophthalmology device business. 

By Lisa LaMotta • June 29, 2018

Biogen pays $700M to up stake in Samsung Bioepis

But the investment might not be for the long term. Biogen has signaled it might seek to trade or otherwise exit the joint venture down the road. 

By Ned Pagliarulo • June 29, 2018

Valeant's Salix strikes deal to promote opioid withdrawal drug

The pact for the first non-opioid to support opioid withdrawal could speed Lucemyra to U.S. patients.

By Suzanne Elvidge • June 29, 2018

Akebia, Keryx to merge, creating $1B kidney disease company

The union may help the two better compete with bigger renal market rivals such as Amgen, Fibrogen and GlaxoSmithKline.

By Ned Pagliarulo • June 28, 2018

GE to spin off healthcare unit in latest restructuring

Moody's and investors applauded the move, which comes amid a reboot of the health division.

By Meg Bryant • June 27, 2018

Roche buys out Foundation Med in $2.4B bet on targeted cancer treatment

Over the past half year, Roche has spent $6 billion on investments aimed at building a lead in the industry's shift toward more personalized medicine.

By Ned Pagliarulo • June 19, 2018

AMAG divests Cord Blood Registry for $530M

The sell-off of the stem cell firm will tighten AMAG's focus on pharmaceuticals and help pay down debt.

By Suzanne Elvidge • June 18, 2018

Prescribed Reading: J&J sells off units; another Alzheimer's defeat

Big pharma extended its string of divestitures and portfolio streamlining this week. Meanwhile, manufacturers can't seem to beat Alzheimer's disease.

By Lisa LaMotta • June 15, 2018

Sage licenses out depression drug in Asia, adding to cash warchest

Inking a deal with Shionogi for rights to SAGE-217, the biotech will earn $90 million upfront just as it preps for a potential market launch of brexanolone. 

By Ned Pagliarulo • June 14, 2018

BridgeBio launches another biotech, focused on gene disorders

CoA Therapeutics, the second subsidiary BridgeBio has rolled out this month, aims to create drugs for diseases linked to coenzyme-A deficiencies.

By Suzanne Elvidge • June 14, 2018

BridgeBio launches new biotech to develop Alexion drug

The biotech parent company took a well-worn route in creating its latest subsidiary, back-stopping it with cash and building it around an acquired asset for an ultra-rare disease. 

By Suzanne Elvidge • June 12, 2018

Axovant stock rockets up on Oxford gene therapy deal

A new addition to its pipeline signals the biotech is still forging ahead despite a recent Alzheimer's trial blowup.

By Suzanne Elvidge • June 7, 2018

BIO18: Pfizer (sort of) inches back to neuro; Building ties with FDA

Day Three of the BIO International convention shined a light on the neuroscience space and its evolution.

By Lisa LaMotta • June 6, 2018

BIO18: Oncology surplus could drive down values

An annual report from Syneos Health shows 2018 could be the second strongest year for dealmaking in the last decade. 

By Lisa LaMotta • June 5, 2018

Versartis stock climbs on reverse merger with Aravive

The two plan to link up to create a publicly listed, clinical-stage oncology biopharma.

By Suzanne Elvidge • June 5, 2018

BIO18: Pfizer's Bourla on volume vs. value

Day One at the BIO International annual convention was dominated by talk of partnering and the changing model for valuing medicines. 

By Lisa LaMotta • June 4, 2018

Prescribed Reading: M&A slow ahead of BIO, ASCO

With two of the industry's biggest conferences coming up, the biopharma deal space took a breath. 

By Lisa LaMotta • June 1, 2018

GE Healthcare supports cell therapy scale-up

A partnership between DiscGenics, CCRM and GE Healthcare could help streamline manufacturing for the disc disease cell therapy.

By Suzanne Elvidge • May 31, 2018

Prescribed Reading: J&J seen with most M&A potential; Drug pricing plan ripples

The pharma giant has the greatest flexibility to ink a deal, according to a recent Leerink report. Elsewhere, drug pricing remained center stage in D.C. 

By Lisa LaMotta • May 25, 2018

AstraZeneca expands development deal with Bicycle

Aiming to bolster its respiratory and cardio-metabolic pipeline, the British pharma has broadened its collaboration with Bicycle to include more targets.

By Lisa LaMotta • May 24, 2018

Cleveland Clinic launches new biorepository

Increased access to tissue sample storage and improved patient consent could speed up translational research.

By Suzanne Elvidge • May 24, 2018

Bioasis signs manufacturing deal with WuXi Biologics

Partnering with the Chinese CDMO should help Bioasis move one of its preclinical drug programs into the clinic.

By Suzanne Elvidge • May 23, 2018

Celgene taps Evotec for oncology discovery

Looking to reduce dependence on Revlimid, the big biotech is working to expand its oncology capabilities.

By Lisa LaMotta • May 22, 2018

Takeda makes $280M divestiture amid Shire buy

While working to close its $62B deal for Shire, the Japanese pharma will sell its majority stake in Guangdong Techpool Bio-Pharma.

By Suzanne Elvidge • May 22, 2018